What’s new in dermatology?

new in dermatology

Dermatology is a field that never stands still, with continuous advancements and breakthroughs improving our understanding and treatment of skin conditions.

In this blog, we’ll explore some of the latest developments in dermatology, and what we can expect from future treatments.

Ruxolitinib approved to treat vitiligo

Vitiligo causes white patches on the skin due to the loss of pigmentation when melanocytes, the cells responsible for skin colour, stop working or are destroyed. While its exact cause remains a mystery, it’s often linked to autoimmune activity.

Ruxolitinib, initially used to treat certain blood disorders, now offers hope for vitiligo patients by promoting repigmentation. The drug targets and blocks the immune pathways that are believed to be overactive in Vitiligo, aiding in stopping its progression and encouraging the skin’s natural colour to return.

Patients with vitiligo will welcome this new treatment option which was approved in the USA by the FDA. It is not currently available for prescribing on the NHS and is in the process of re-appraisal by the National Institute of Health and Care Excellence (NICE).

Ritlecitinib recommended by NICE to treat severe alopecia areata

Alopecia areata causes hair loss, typically in patches, as the immune system mistakenly targets its own cells, including the hair follicles. This condition can escalate to complete hair loss on the scalp and body, significantly impacting self-esteem and quality of life.

Ritlecitinib has recently been recognised by NICE as a new treatment option for severe alopecia areata. Acting as a Janus kinase (JAK) inhibitor, it intervenes in the immune pathways responsible for hair loss.

Treating alopecia areata with Ritlecitinib is convenient, requiring just one pill daily, making it a user-friendly and effective approach for those grappling with this condition.

What other developments are making waves in dermatology?

There are currently several developments being worked on in the field of dermatology including a promising treatment for psoriasis. A study involving 255 patients (still ongoing) demonstrated that a targeted oral peptide inhibitor, the first of its kind, blocks IL-23 receptors and pathogenic T-cell activation, with no safety concerns. This could lead to improved treatments for psoriasis patients as well those with other immune mediated inflammatory diseases.

New findings from another study presented at the annual American Academy of Allergy, Asthma & Immunology (AAAI) meeting, also recommended PH labelling of liquid synthetic detergents on skin cleansers could be helpful for those with atopic dermatitis when checking products for acidity. These developments in dermatology are just a glimpse into ongoing investigations and discoveries.

If you’re facing skin issues, don’t hesitate to make an appointment with Dr Juliet Williams. She will be happy to help you with your skin concerns and if needed she can create a customised treatment plan for helping you manage the problem.